Antimetabolite. Azacitidine 100 mg.
VIAL (Lyophilized pwdr. for suspens. for SC Inj./sol. for infus.): 1. 1^st tmt. cycle, for all pts. regardless of baseline hematology lab. values, is 75 mg/m² SC or IV, daily for 7 d. Premedicate pts. for nausea & vomit.
Obtain complete blood counts, hep. enzym., serum creatinine prior to the 1^st dose.
Subseq. Tmt. Cycles: Repeat cycles every 4 wks. The dose may be incr. to 100 mg/m² if no beneficial effect is seen after 2 tmt. cycles and if no toxicity other than nausea & vomit. has occurred. It is recomm. that pts. be treated for a min. of 4-6 cycles. However, complete or partial response may require addit. tmt. cycles. Tmt. may be continued as long as the pt. continues to benefit.
Tmt. of pts. with the following French-American-British (FAB) myelodysplastic syndr. subtypes: refract. anemia (RA) or refract. anemia with ringed sideroblasts (if accompan. by neutrop. or thrombocytop. or require. transfusions), refract. anemia with excess blasts (RAEB), refract. anemia with excess blasts in transformation (RAEB-T), and chron. myelomonocytic leukem. (CMMoL).
C/I: Hypersens. Pts. with advanced malig. hep. tumors.

Tick-borne encephalitis (TBE) vaccine. Tick-Borne Encephalitis Virus 2.4 mcg.
PRE-FILLED SYR. (susp. for inj.): 1. The 1^st & 2^nd dose should be given at a 1-3 month interval. If there is a need to achieve an immune response rapidly, the 2^nd dose may be given two weeks after the 1^st dose. After the 1^st two doses suffic. protect. for the ongoing tick season is to be expected.
The 3^rd dose should be given 5 to 12 mnths. after the 2^nd vaccin. After the 3^rd dose protection is expected to last for at least 3 yrs.
1^st dose, 0.5 ml on the elected date 2^nd  dose, 0.5 ml -1 to 3 mnths. after the 1^st vaccine. (rapid vaccin. schedule -14 days after the 1^st vaccin.).
3^rd dose, 0.5 ml- 5 to 12 mnths. after the 2^nd vaccin. (rapid vaccin. schedule- 5 to 12 mnths. after the 2^nd vaccin.).
Booster doses: Persons from 16-60 yrs. of age: The 1^st booster dose should be given 3 yrs. after the third dose.
Sequent. booster doses should be given every 5 yrs. after the last booster dose.
Booster dose 16 to<60 yrs.: 1^st booster  0.5 ml -3 years after the 3^rd vaccin.
Sequent. booster doses 0.5 ml every 5 yrs.
Booster dose ≥ 60 yrs.: All booster doses 0.5 ml - every 3 yrs.
Active (prophylactic) immunization of adolescents from 16 years of age and adults against tick-borne encephalitis (TBE).
The vaccine is to be given on the basis of official recommendations regarding the need for, and timing of, vaccination against TBE.
C/I: Hypersens. Cross allergies with aminoglycosides other than neomycin and gentamycin.
Severe hypersens. egg, chick proteins (anaphyl. reaction after oral ingest. of egg protein) may cause severe allergic react. in sensitized individ.
TBE vaccine. should be postponed if the person is suffer. from a moder. or severe acute illness (with/without fever).

Tick-borne encephalitis (TBE) vaccine. Tick-Borne Encephalitis Virus 1.2 mcg.
PRE-FILLED SYR. (susp. for inj.): 1. The primary vaccine. schedule is the same for all persons from 1- 15 yrs. of age and consists of three doses of this vaccine.
The 1^st and 2^nd dose should be given at a 1-3 mnth. interval.
If there is a need to achieve an immune response rapidly, the 2^nd dose may be given two wks. after the 1^st dose. After the 1^st two doses a sufficient protect. for the ongoing tick season is to be expected.
The 3^rd dose should be given 5-12 mnths. after the 2^nd vaccinat. After the 3^rd dose protect. is expected to last for at least 3 yrs. See lit.
Indicated for the active (prophylactic) immunization of children aged from 1-15 yrs. against tick-borne encephalitis (TBE). This vaccine is to be given on the basis of official recommendat. regarding the need for, and timing of, vaccinat. against TBE.
C/I: Hypersens. Cross allergies with aminoglycosides other than neomycin and gentamycin. Severe hypersens. egg, chick proteins (anaphyl. reaction after oral ingest. of egg protein) may cause severe allergic react. in sensitized individ.
TBE vaccine. should be postponed if the person is suffer. from a moder. or severe acute illness (with/ without fever).

Prostaglandin, β Blocker. Bimatoprost 0.3 mg/ml, Timolol Maleate 5 mg/ml.
BOTTLE: 3 ml. 1 dr.×1/d, in the morn. or in the eve., in each eye that requires tmt.
Reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.
C/I: Hypersens. to bimatoprost, timolol, beta block. Pts. with respirat. disord. such as asthma or severe COPD. Patients with cardiac disorders such as bradycardia, heart block or heart failure. Lact.

Bradykinin B2 Receptor Antagonist. Icatibant (as acetate) 30 mg / 3 ml.
SYR. (Sol. for S.C. inj.).: 1. One S.C. inj. of Icatibant (3 ml/30 mg), as soon as signs of attack are detected (e.g. swelling of the skin, especially in the area of the face and neck, or increas. abdom. pain).
If the condition is not improved in 6 hrs., another 3 ml dose may be admin.
If there is still no improv., a 3^rd dose may be admin. after another 6 hrs.
No more than 3 doses in 24 hrs. and no more than 8 inj. of icatibant in one month. See lit.
Tmt. of acute attacks of hereditary angioedema (HAE) in adults 18 yrs. of age and older.
C/I: Hypersens.

Anti-CD33. Gemtuzumab Ozogamicin 5 mg.
VIAL (Pwdr. for concent. for sol. for infus.): 1×4.5 mg. Dosage must be adjust. individual.
Newly-Diagnosed CD33-positive Acute Myeloid Leukemia (AML): MYLOTARG is indicated for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults.
Relapsed or Refractory CD33-positive AML: MYLOTARG is indicated for the treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older.
C/I: Hyperses.